Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

In Vivo’s Deals Of The Year 2021: Cast Your Vote!

Jan 13 2022

• By Andrew Odame-Kwakye

In Vivo's Deal of the Year

Related Content

Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Jul 22 2021

Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy

Feb 04 2021

Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model

Feb 18 2021

Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

Mar 04 2021

Sanofi Goes All The Way In mRNA With Translate Bio Buy

Aug 03 2021

The Inexorable Rise Of Exscientia

Oct 06 2021

Novartis Expands BeiGene Tie-Up To TIGIT Inhibitor In $1bn-Plus Option Deal

Dec 21 2021

AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate

Dec 07 2021

Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics

Oct 28 2020

Procept BioRobotics Seeks $164M To Go Public

Sep 16 2021

Related Companies

Ionis Pharmaceuticals, Inc.

AstraZeneca PLC

Arvinas, Inc.

Pfizer Inc.

Recursion Pharmaceuticals, Inc.

Roche Holding AG

Novartis AG

BeOne Medicines Ltd.

Olympus Corporation

Centessa Pharmaceuticals plc

Exscientia plc

Sana Biotechnology, Inc.

Rectify Pharmaceuticals, Inc.

PROCEPT BioRobotics

Merck & Co., Inc.

Acceleron Pharma, Inc.

Exact Sciences Corp.

Thrive Earlier Detection Corp.

Translate Bio

Amgen, Inc.

Five Prime Therapeutics, Inc.

Jazz Pharmaceuticals plc

GW Pharmaceuticals plc

Additional Topics

Deals M & A Financing Commercial Companies Market Intelligence BioPharmaceutical Medical Device

More from Deal-Making

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window